Our Commitment to Biosimilars

Learning from the past, developing for the future.

Amgen was one of the first companies to recognize the potential of modern biotechnology in developing valuable medicines for patients – and to assemble the diverse set of skills necessary to advance from textbook to applied science. Today, we are applying our deep scientific capabilities from more than three decades of experience to the development of biosimilars and continuing our legacy of providing patients with vital medicines.


Amgen’s core focus is to discover, develop and deliver innovative medicines for patients with grievous illnesses. Biosimilars have the potential to bring increased access of our medicines to a broader patient population.  Because biosimilars are so difficult and expensive to develop, manufacturers will need to have significant biologics expertise, infrastructure and capital investment to successfully bring these medicines to market.

That is why we at Amgen have committed the best scientists and the necessary investments to produce reliably supplied, high-quality biosimilars. Learn more about the importance of reliable supply to patients and our dedication to addressing this societal concern.

We are investing over $1 billion into the development of our biosimilars portfolio to target many of the most complex diseases in oncology and inflammation, such as breast cancer, rheumatoid arthritis and many more.

Additionally, we work with a variety of partners to expand our ability to capitalize on innovations that have the potential to deliver tangible benefits to those suffering from serious illness. Leveraging our leading position in biotechnology, we employ scientists to focus on producing biosimilars. Many of our scientists have decades of experience and some have experience dating back to the creation of medical biotechnology. We have also partnered with Actavis on our biosimilar oncology programs, which brings together Amgen’s more than 35 years of experience in biologics R&D and manufacturing as well as Actavis’ substantial generics and specialty pharmaceutical experience.

At the heart of Amgen’s commitment to biosimilars is our mission to serve patients. Biosimilars have the potential to expand access to important therapeutics and we believe we are bringing the highest quality science to this new space in healthcare.

Frederick

Molecular Biology 34 years of experience

Christian

Drug Product Engineering 12 years of experience

Vincent

Pharmacokinetics 15 years of experience

Tamer

Analytical Sciences 21 years of experience

Kristine

Cell Line Development 14 years of experience

Shawn

Product Development 17 years of experience

Marta

Clinical Immunology 9 years of experience

Katariina

Analytical Sciences 14 years of experience

Jerad

Operations 13 years of experience

Teresa

Functional Biology 17 years of experience

Heather

Functional Biology 10 years of experience

Vladimir

Clinical Development 20 years of experience

John L

Product Quality 17 years of experience

Roy

Drug Product Engineering 8 years of experience

Junfen

Purification Processes 11 years of experience

Richard

Clinical Development 18 years of experience

Steven

Drug Product Engineering 7 years of experience

Margaret

Process Development 18 years of experience

Jyoti

Functional Biology 14 years of experience

Jennifer

Analytical Sciences 23 years of experience

Brad

Supply Chain 14 years of experience

Michael

Clinical Immunology 20 years of experience

Vineetha

Functional Biology 15 years of experience

Suresh

Process Development 18 years of experience

Darin

Product Quality 21 years of experience

Venkat

Operations 15 years of experience

Paul

Operations 15 years of experience

Susan

Product Quality 21 years of experience

Lowell

Analytical Sciences 15 years of experience

Jeff

Operations 19 years of experience

Spiro

Process Engineering 22 years of experience

Gay

Operations 20 years of experience

Primal

Clinical Development 5 years of experience

Victor

Process Development 32 years of experience

Linda

Operations 20 years of experience

Amgen is committed to biosimilars. We currently have a robust pipeline with several biosimilar molecules in development which target some of the most complex and important oncology and inflammation antibody biologics.

FIND OUT MORE INFORMATION ON OUR PIPELINE